Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
11
05
2023
accepted:
23
06
2023
medline:
12
10
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
ppublish
Résumé
Sentinel lymph node (SLN) biopsy has recently been accepted to evaluate nodal status in endometrial cancer at early stage, which is key to tailoring adjuvant treatments. Our aim was to evaluate the national implementation of SLN biopsy in terms of accuracy to detect nodal disease in a clinical setting and oncologic outcomes according to the volume of nodal disease. A total of 29 Spanish centers participated in this retrospective, multicenter registry including patients with endometrial adenocarcinoma at preoperative early stage who had undergone SLN biopsy between 2015 and 2021. Each center collected data regarding demographic, clinical, histologic, therapeutic, and survival characteristics. A total of 892 patients were enrolled. After the surgery, 12.9% were suprastaged to FIGO 2009 stages III-IV and 108 patients (12.1%) had nodal involvement: 54.6% macrometastasis, 22.2% micrometastases, and 23.1% isolated tumor cells (ITC). Sensitivity of SLN biopsy was 93.7% and false negative rate was 6.2%. After a median follow up of 1.81 years, overall surivial and disease-free survival were significantly lower in patients who had macrometastases when compared with patients with negative nodes, micrometastases or ITC. In our nationwide cohort we obtained high sensitivity of SLN biopsy to detect nodal disease. The oncologic outcomes of patients with negative nodes and low-volume disease were similar after tailoring adjuvant treatments. In total, 22% of patients with macrometastasis and 50% of patients with micrometastasis were at low risk of nodal metastasis according to their preoperative risk factors, revealing the importance of SLN biopsy in the surgical management of patients with early stage EC.
Sections du résumé
BACKGROUND
BACKGROUND
Sentinel lymph node (SLN) biopsy has recently been accepted to evaluate nodal status in endometrial cancer at early stage, which is key to tailoring adjuvant treatments. Our aim was to evaluate the national implementation of SLN biopsy in terms of accuracy to detect nodal disease in a clinical setting and oncologic outcomes according to the volume of nodal disease.
PATIENTS AND METHODS
METHODS
A total of 29 Spanish centers participated in this retrospective, multicenter registry including patients with endometrial adenocarcinoma at preoperative early stage who had undergone SLN biopsy between 2015 and 2021. Each center collected data regarding demographic, clinical, histologic, therapeutic, and survival characteristics.
RESULTS
RESULTS
A total of 892 patients were enrolled. After the surgery, 12.9% were suprastaged to FIGO 2009 stages III-IV and 108 patients (12.1%) had nodal involvement: 54.6% macrometastasis, 22.2% micrometastases, and 23.1% isolated tumor cells (ITC). Sensitivity of SLN biopsy was 93.7% and false negative rate was 6.2%. After a median follow up of 1.81 years, overall surivial and disease-free survival were significantly lower in patients who had macrometastases when compared with patients with negative nodes, micrometastases or ITC.
CONCLUSIONS
CONCLUSIONS
In our nationwide cohort we obtained high sensitivity of SLN biopsy to detect nodal disease. The oncologic outcomes of patients with negative nodes and low-volume disease were similar after tailoring adjuvant treatments. In total, 22% of patients with macrometastasis and 50% of patients with micrometastasis were at low risk of nodal metastasis according to their preoperative risk factors, revealing the importance of SLN biopsy in the surgical management of patients with early stage EC.
Identifiants
pubmed: 37633852
doi: 10.1245/s10434-023-14065-3
pii: 10.1245/s10434-023-14065-3
pmc: PMC10562309
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7653-7662Informations de copyright
© 2023. The Author(s).
Références
Int J Gynecol Pathol. 2018 May;37(3):242-251
pubmed: 28700425
Gynecol Oncol. 2019 Jun;153(3):496-499
pubmed: 31230614
Lancet Oncol. 2011 May;12(5):469-76
pubmed: 21489874
Gynecol Oncol. 2019 Sep;154(3):475-479
pubmed: 31345606
Eur J Obstet Gynecol Reprod Biol. 2022 Jul;274:68-72
pubmed: 35598492
J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16
pubmed: 19033573
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Gynecol Oncol. 2021 Sep;162(3):590-598
pubmed: 34274133
Ann Surg Oncol. 2015 Mar;22(3):980-6
pubmed: 25190122
Int J Gynecol Cancer. 2021 May;31(5):744-753
pubmed: 33187974
Cancers (Basel). 2021 Sep 04;13(17):
pubmed: 34503275
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Eur J Cancer. 2019 Jul;116:77-85
pubmed: 31181536
JAMA Surg. 2021 Feb 1;156(2):157-164
pubmed: 33175109
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Lancet Oncol. 2018 Oct;19(10):1394-1403
pubmed: 30143441
Ann Surg Oncol. 2016 May;23(5):1653-9
pubmed: 26714954
Cochrane Database Syst Rev. 2021 Jun 9;6:CD013021
pubmed: 34106467
Ann Oncol. 2016 Jan;27(1):16-41
pubmed: 26634381
Int J Gynecol Cancer. 2017 Jul;27(6):1165-1170
pubmed: 28604450
Gynecol Oncol. 2017 Aug;146(2):240-246
pubmed: 28577885
J Gynecol Oncol. 2022 Mar;33(2):e11
pubmed: 34910392
Int J Gynecol Cancer. 2019 Mar;29(3):613-621
pubmed: 30712017